Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spotlight on Q1 Pharma M&A Merry-Go-Round

Executive Summary

Q1 2019 saw a jump in merger and acquisition activity. Informa’s Biomedtracker has cast an analytical eye on three of the major deals, namely buys by Roche, Lilly and BMS.

You may also be interested in...



Deal Watch: Vertex Expands Gene-Editing Efforts With A Pair Of Deals

CF-focused Vertex will buy Exonics and expand a collaboration with CRISPR Therapeutics, with plans to develop therapies for DMD and myotonic dystrophy type 1. Merck acquires TGFβ-focused Tilos, while Achaogen offloads most of its assets at auction.

BioMarin Says It's Got The Hemophilia Therapy Data For Approval And Value

The company will begin discussions with regulators in the US and Europe for a gene therapy for hemophilia A based on the results of new data, with a launch targeted for late 2020. Durability remains a question.

As Expected: Shareholders Back Bristol's $74bn Celgene Buy

With no more activist investor challenge, shareholders of both companies overwhelmingly approved the deal. Bristol said it will have leading positions in oncology and cardiovascular disease, and gain five potential blockbusters in the Celgene buyout.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC125339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel